BioNexus Issues $800K in Stock Awards, Reappoints CEO, and Reiterates Going Concern Doubt
BGLC sits 47% above its 52-week low of $1.07.
Summary
BioNexus Gene Lab Corp reported a 97.75% revenue collapse and $830,026 net loss for H1 2026, reiterated going concern doubt, disclosed an unremediated material weakness, and issued $800K in stock awards to insiders while reappointing its CEO.
Key Events · Earnings and Guidance · BGLC
-
Revenue Collapse
Revenue fell 97.75% YoY to $98,998 for H1 2026, driven by a 97.79% decline at Chemrex due to actions of former management.
-
Going Concern Doubt
Net loss of $830,026 and accumulated deficit of $7,257,253 raise substantial doubt about the company's ability to continue as a going concern within one year.
-
Material Weakness Unremediated
Internal control over financial reporting at Chemrex subsidiary remains ineffective; remediation plan ongoing but not yet complete.
-
Insider Stock Awards
On August 13, 2026, the company issued 516,128 fully vested shares to CEO, CFO, and three directors, valued at $799,998.40 ($1.55/share), increasing outstanding shares by 21.3%.
Analysis · BGLC · Industrial Applications And Services
The 10-Q reveals a near-total revenue collapse (down 97.75% YoY to $98,998 for H1 2026), a net loss of $830,026, and an accumulated deficit of $7.26 million, with management again raising substantial doubt about the company's ability to continue as a going concern. The material weakness in internal controls at Chemrex remains unremediated. On August 13, 2026, the company issued 516,128 fully vested shares to executives and directors valued at $799,998.40, increasing outstanding shares by 21.3% to 2,933,442. CEO Su-Leng Tan Lee was reappointed for a three-year term with a $35,000 monthly salary. These disclosures are highly material for a micro-cap company with a market cap of only $3.8 million.
At the time of this filing, BGLC was trading at $1.57 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $1.07 to $6.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.